The Global Health Body Issues Warning Over Critical Lack of Obesity Jabs

Less than one in 10 individuals that would benefit from GLP-1 drugs such as Wegovy are able to get them, caution the World Health Organization as it publishes its initial guidance on the therapies.

Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging increased and just access to these injectable treatments.

According to estimates, more than two billion could be obese by 2030 if no action is taken.

"Our new guidelines recognises that obesity is a chronic disease that can be addressed with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and logistical bottlenecks are key hurdles to universal access to the jabs that can help people shift considerable weight, notes the agency.

Weight-Loss Drug Scarcity

Even under the present most favorable case, the manufacturing of these medications would only suffice for around 100 million people – fewer than 10% of eligible patients, according to the WHO.

The guideline urges countries and companies to increase availability, through approaches such as patent sharing.

A patent on semaglutide – the primary component of the drug Wegovy – is set to lapse in multiple nations in 2026.

How Weight-Loss Jabs Work

These medications mimick a biological compound to reduce digestion speed, reduce hunger and enhance satiety so people reduce food intake.

Individuals usually see weight reduction after several weeks of commencing the once-weekly jabs.

Studies indicates patients may see weight return after a year of halting the medication, as their usual food cravings come back.

To be above a healthy weight elevates your likelihood for contracting health problems, like diabetes, cardiovascular issues, brain attack, and some malignancies.

Obesity impacts individuals in all nations and was responsible for millions of fatalities worldwide in 2024, per the health agency.